Financing - January 12, 2026
EpiEndo completes a EUR 9 million convertible bond issue
The company has raised EUR 5 million of new funding from new and existing investors via a EUR 9 million convertible bond issuance.
Clinical Trials - January 12, 2026
Elicera Therapeutics announces final data from its Phase I/IIa trial
Elicera Therapeutics has announced final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases.
Science News - January 12, 2026
Risk of multimorbidity predicted with blood test
A small set of common blood biomarkers predicts which older adults will develop specific combinations of chronic diseases, and how quickly, a new Swedish study shows.
Business article - January 9, 2026
PCI Biotech discontinues R&D operations
The company's external evaluation of a new bioprocessing technology has been concluded, with no prospects for further collaboration.
In a new job - January 9, 2026
AstraZeneca appoints Head of Investor Relations
AstraZeneca’s new head of Investor Relations, Joris Silon, succeeds Andy Barnett on 1 March 2026, and will be based in Cambridge, UK.
Collaboration - January 9, 2026
Mavatar and Sobi collaborate
The collaboration will explore interferon gamma (IFNγ)-associated biological pathways using Mavatar’s large-scale analysis platform, which integrates and contextualizes publicly available transcriptomic datasets.
